Stock Taper
SCREENER COMPARE ANY 2 STOCKS
INBX
INHIBRX BIOSCIENCES INC.
NASDAQ
$123.41
▼ DOWN 0.42% (-0.52)

KEY STATISTICS

Market Cap$1.81 B
52w High$155.29
52w Low$26.19
Dividend Yield5.23%
FrequencySpecial
P/E-13.90
Volume241.48K
Shares Out.14.67M

COMPANY

LEADERSHIP

Mark Paul Lappe
CHIEF EXECUTIVE
Mark Paul Lappe

COMPENSATION 2026

Salary$695,250
Stock Awards$0
Incentive Plan Pay$479,723
All Other Comp.$17,500
Total$2,892,473

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 29, 2024
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
110

PRICE TARGET

Target High$325.00
Target Low$245.00
Target Median$285.00
Target Consensus$285.00

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.$1.90M
NOV
13
FRI

PRICE

$123.41 ▼ DOWN 0.42% (−$0.52)
$120$122$124$1269:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM123.41

About Inhibrx Biosciences Inc.

https://www.inhibrx.com ↗

Inhibrx Biosciences, a 2024-launched La Jolla-based biotech, develops biologic therapeutics like INBRX-109 and INBRX-106, currently in phase 2 trials for various metastatic and solid tumor cancers.

INDUSTRY

Biotechnology

A PRODUCT INHIBRX BIOSCIENCES INC. IS KNOWN FOR

ozekibart (INBRX-109)
ozekibart (INBRX-109)

Ozekibart, a tetravalent DR5 agonist by Inhibrx, is developed for cancers like chondrosarcoma, colorectal, and Ewing sarcoma, having met primary endpoints in trials and planning FDA BLA submission in Q2 2026.

COMPETITORS

COMPETITOR
KPTI COMPARE
MGNX COMPARE

Revenue by Products

IconPRODUCTQ4-2024Q2-2025Q3-2025Q4-2025
License NonAffiliate$100K $1.3M ▲$1.3M $0 ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
112
LISTED HERE
20
RANKED BY POSITION SIZE
XBI
0.44% · 427.8K
VTS.AX
0.00% · 369.6K
IWM
0.04% · 243.9K
FYC
0.68% · 80.2K
USVM
0.18% · 26.3K
LABU
0.30% · 15.5K
PRFZ
0.05% · 10.9K
XRSU.L
0.04% · 8.7K
GSSC
0.09% · 7.9K
CANC
0.41% · 7.1K
ONEQ
0.01% · 4.9K
RSSL
0.04% · 4.5K
BBC
0.80% · 3.4K
BIB
0.06% · 523
VETS
0.10% · 241
QSML
0.19% · 182
KBFR
0.06% · 50
AVUQ
0.00% · 36
USUE.DE
0.00% · 31
RESM
0.04% · 21

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.32%
HOLDERS
210
TOP 12 OF 210 · RANKED BY POSITION SIZE
Viking Global Investors LP
1.8M sh · $60.21M
Perceptive Advisors LLC
1.5M sh · $114.76M
Morgan Stanley
1.3M sh · $123.94M
Sanofi
1.2M sh · $109.71M
Hightower Advisors, LLC
871.8K sh · $29.36M
Bank Of America Corp /De/
841.1K sh · $79.7M
Blackrock, Inc.
826.0K sh · $78.26M
Schonfeld Strategic Advisors LLC
697.6K sh · $66.1M
Blackrock Inc.
683.1K sh · $9.68M
State Street Corp
640.5K sh · $60.68M
Vanguard Group Inc
623.1K sh · $49.22M
Sofinnova Investments, Inc.
454.7K sh · $35.92M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Vuori Kristiina MD
Purchase · 15.0K shares
2026-06-03
★
DIRECTOR
Kayyem Jon Faiz
Purchase · 15.0K shares
2026-06-03
★
DIRECTOR
FORSYTH DOUGLAS
Purchase · 15.0K shares
2026-06-03
★
DIRECTOR
MANHARD KIMBERLY
Purchase · 15.0K shares
2026-06-03

SECTORS PEERS

PEERPRICE
ELVN$57.86COMPARE
RLAY$18.77COMPARE
AMLX$34.74COMPARE
ATAI$7.29COMPARE
NKTR$72.52COMPARE
SNDX$19.54COMPARE
ORIC$13.24COMPARE
IMTX$9.45COMPARE